NCT05859269 is a Phase 4 clinical trial of Methylprednisolone in Knee Arthritis, sponsored by Emory University.

Who is sponsoring NCT05859269?

NCT05859269 is sponsored by Emory University.

What drugs are being tested in NCT05859269?

Interventions in NCT05859269: Methylprednisolone, Standard of Care.

What condition does NCT05859269 study?

NCT05859269 studies Knee Arthritis.

Is NCT05859269 still recruiting?

NCT05859269 is currently completed. Last updated 18 September 2025.

Last reviewed 2025-09-18 · How we verify

NCT05859269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Methylprednisolone Taper After Total Knee Replacement

Completed Phase 4 Last updated 18 September 2025

What this trial tests

Phase 4 trial testing Methylprednisolone in Knee Arthritis in 101 participants. Completed in 23 July 2025.

Timeline

16 October 2023

Primary endpoint
23 July 2025

23 July 2025

Quick facts

Lead sponsor	Emory University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	101
Start date	16 October 2023
Primary completion	23 July 2025
Estimated completion	23 July 2025
Sites	2 locations across United States

Drugs / interventions tested

Methylprednisolone (methylprednisolone) — full drug profile →
Standard of Care

Conditions studied

Knee Arthritis — all drugs for Knee Arthritis →

Sponsor

Emory University

Who can join

Adults 18 to 95, any sex, with Knee Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Total knee replacement surgery is a commonly performed and widely successful surgery to improve mobility and decrease pain in patients suffering from severe knee arthritis. However, in the immediate period after knee replacement, patients often experience significant pain and nausea, which can limit early recovery after surgery. Glucocorticoids are anti-inflammatory drugs that can reduce pain and swelling by blocking the inflammatory process, and have already shown promise in various surgical settings, including after knee replacement. There are different glucocorticoid formulations available, and in this particular study, we are evaluating the effects of administering a Medrol Dose Pak, which is a commonly available glucocorticoid taper that is administered over a short period of time after surgery. Our hypothesis is that the administration of the Medrol Dose Pak will lead to decreased pain, nausea, and opioid consumption in the weeks following total knee replacement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Postoperative Oral Corticosteroids for Pain Management and Recovery After Total Knee Arthroplasty: A Systematic Review.
Vingerhoets T, Gazali I, Vingerhoets K, Platteau W. · · 2026 · PMID 42222636 · DOI 10.7759/cureus.109813

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Ped · Phase 2 · not yet recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
NCT07265258 — A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease · Phase 4 · not yet recruiting

Other recruiting trials for Knee Arthritis

Currently open trials in the same condition.

NCT05543941 — Evaluating XPERIENCE™ Advanced Surgical Irrigation · NA · recruiting
NCT04018638 — Blood-Flow Restriction Exercise Following a Knee Replacement · NA · active not recruiting
NCT03211663 — Performance of MOTO Medial® Unicompartmental Knee Arthroplasty · active not recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05859269 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 18 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05859269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing